Can I read Cost-effectiveness Analysis of Sintilimab Plus Bevacizumab Biosimilar Compared with Lenvatinib as the First-line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma on EtoBox?

Cost-effectiveness Analysis of Sintilimab Plus Bevacizumab Biosimilar Compared with Lenvatinib as the First-line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma by Ting Zhou; Xintian Wang; Yingdan Cao; Lan Yang; Zijing Wang; Aixia Ma; Hongchao Li is a Health Professions article available to read on EtoBox.

What is Cost-effectiveness Analysis of Sintilimab Plus Bevacizumab Biosimilar Compared with Lenvatinib as the First-line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma about?

## Abstract ## Background In recent years, programmed cell death protein-1 inhibitors, including sintilimab, have significantly prolonged the overall survival time of patients with unresectable or metastatic hepatocellular carcinoma (HCC); however, the cost-effectiveness of sintilimab is unclear. The aim of this study was to assess the cost-effectiveness of sintilimab plus bevacizumab biosimilar compared with lenvatinib as first-line treatment in patients with unresectable or metastatic HCC. ## Methods A lifetime partitioned survival model was developed to conduct a cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar vs. lenvatinib for advanced HCC from a Chinese healthcare system perspective. The clinical and safety data were derived from two recent randomized clinical trials, the ORIENT-32 and REFLECT studies. Utility data were obtained from previous studies. Long-term direct medical costs and quality-adjusted life-years (QALYs) were predicted. Deterministic and probabilistic sensitivity analyses were performed to verify the robustness of the model. ## Results Compared with lenvatinib, combination therapy with sintilimab and bevacizumab biosimilar yielded an add

Who reads Cost-effectiveness Analysis of Sintilimab Plus Bevacizumab Biosimilar Compared with Lenvatinib as the First-line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma?

Author

Ting Zhou; Xintian Wang; Yingdan Cao; Lan Yang; Zijing Wang; Aixia Ma; Hongchao Li

Publisher

Springer Science and Business Media LLC

Published

2022

Language

EN

Field

Health Professions (Health Sciences)